Research ExplorerPublicationsImpact of HPV status on treatment of squamous cell cancer of...

Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.

Standard

Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. / Tribius, Silke; Ihloff, Anna-Sophie; Rieckmann, Thorsten; Petersen, Cordula; Hoffmann, Markus.

In: CANCER LETT, Vol. 304, No. 2, 2, 2011, p. 71-79.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tribius, S, Ihloff, A-S, Rieckmann, T, Petersen, C & Hoffmann, M 2011, 'Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.', CANCER LETT, vol. 304, no. 2, 2, pp. 71-79. <http://www.ncbi.nlm.nih.gov/pubmed/21376458?dopt=Citation>

APA

Tribius, S., Ihloff, A-S., Rieckmann, T., Petersen, C., & Hoffmann, M. (2011). Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. CANCER LETT, 304(2), 71-79. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21376458?dopt=Citation

Vancouver

Tribius S, Ihloff A-S, Rieckmann T, Petersen C, Hoffmann M. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. CANCER LETT. 2011;304(2):71-79. 2.

Bibtex

@article{371d677f126648bca91d151859db0233,
title = "Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.",
abstract = "Studies report an increasing incidence of oropharyngeal cancers linked to infection by human papillomavirus (HPV). We reviewed trials assessing outcomes by HPV DNA status in patients with locally advanced oropharyngeal cancer. Seven of the eight studies identified showed significantly better survival in patients with HPV DNA-positive tumors vs. HPV DNA-negative tumors. The review also describes what needs to be defined regarding optimal treatments. Future trials should incorporate HPV DNA status as a risk determinant and explore treatments for high-risk patients needing therapy intensification, and low- and intermediate-risk patients needing treatment de-intensification to improve tolerability, without compromising survival.",
author = "Silke Tribius and Anna-Sophie Ihloff and Thorsten Rieckmann and Cordula Petersen and Markus Hoffmann",
year = "2011",
language = "English",
volume = "304",
pages = "71--79",
journal = "CANCER LETT",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.

AU - Tribius, Silke

AU - Ihloff, Anna-Sophie

AU - Rieckmann, Thorsten

AU - Petersen, Cordula

AU - Hoffmann, Markus

PY - 2011

Y1 - 2011

N2 - Studies report an increasing incidence of oropharyngeal cancers linked to infection by human papillomavirus (HPV). We reviewed trials assessing outcomes by HPV DNA status in patients with locally advanced oropharyngeal cancer. Seven of the eight studies identified showed significantly better survival in patients with HPV DNA-positive tumors vs. HPV DNA-negative tumors. The review also describes what needs to be defined regarding optimal treatments. Future trials should incorporate HPV DNA status as a risk determinant and explore treatments for high-risk patients needing therapy intensification, and low- and intermediate-risk patients needing treatment de-intensification to improve tolerability, without compromising survival.

AB - Studies report an increasing incidence of oropharyngeal cancers linked to infection by human papillomavirus (HPV). We reviewed trials assessing outcomes by HPV DNA status in patients with locally advanced oropharyngeal cancer. Seven of the eight studies identified showed significantly better survival in patients with HPV DNA-positive tumors vs. HPV DNA-negative tumors. The review also describes what needs to be defined regarding optimal treatments. Future trials should incorporate HPV DNA status as a risk determinant and explore treatments for high-risk patients needing therapy intensification, and low- and intermediate-risk patients needing treatment de-intensification to improve tolerability, without compromising survival.

M3 - SCORING: Journal article

VL - 304

SP - 71

EP - 79

JO - CANCER LETT

JF - CANCER LETT

SN - 0304-3835

IS - 2

M1 - 2

ER -